OncoTargets and Therapy (Dec 2020)

Profiling Analysis Reveals the Crucial Role of the Endogenous Peptides in Bladder Cancer Progression

  • Li W,
  • Zhang Y,
  • Li Y,
  • Cao Y,
  • Zhou J,
  • Sun Z,
  • Wu W,
  • Tan X,
  • Shao Y,
  • Xie K,
  • Yan X

Journal volume & issue
Vol. Volume 13
pp. 12443 – 12455

Abstract

Read online

Weijian Li,1,* Yang Zhang,1,2,* Youjian Li,1,3,* Yuepeng Cao,4 Jun Zhou,1 Zhongxu Sun,1 Wanke Wu,5 Xiaofang Tan,5 Yang Shao,5 Kaipeng Xie,5,6 Xiang Yan1,2 1Department of Nephrology and Urology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, People’s Republic of China; 2Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, People’s Republic of China; 3Department of Urology Surgery, The People’s Hospital of Xuancheng City, Xuancheng, People’s Republic of China; 4Department of Critical Care Medicine, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, People’s Republic of China; 5Nanjing Maternity and Child Health Care Institute, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; 6Department of Women’s Health Care, The Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xiang YanDepartment of Nephrology and Urology, The Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, People’s Republic of ChinaEmail [email protected] XieNanjing Maternity and Child Health Care Institute, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, The Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University, Nanjing 210004, People’s Republic of ChinaTel/Fax +86-25-5222-6264Email [email protected]: Peptide drugs provide promising regimes in bladder cancer. In order to identify potential bioactive peptides involved in bladder cancer, we performed the present study.Methods: Liquid chromatography/mass spectrometry assay was used to compare the endogenous peptides between bladder cancer and normal control. The potential biological functions of these dysregulated peptides are assessed by GO analysis and KEGG pathway analysis of their precursors. The SMART and UniProt databases are used to identify the sequences of the dysregulated peptides located in the functional domains. The Open Targets Platform database was used to investigate the precursors related to metabolic diseases.Results: A total of 9 up-regulated peptides and 110 down-regulated peptides in bladder cancer compared with normal control were identified (fold change > 1.2, P < 0.05). The MW of these dysregulated peptides ranged from 500 Da to 2500 Da and the MW of all identified peptides was below 3500 Da. The GO and KEGG pathway analysis indicated that these dysregulated peptides could play an important role in bladder cancer. Our further analysis revealed that 45HFNPRFNAHGDAN 57 derived from LGALS1 and those peptides derived from P4HB and SERPINA1 might be the promising diagnostic biomarkers and therapeutic targets of bladder cancer.Conclusion: In the present study, we have identified the profile of the peptides significantly dysregulated in bladder cancer. Moreover, using bioinformatic analysis, we found the peptides derived from LGALS1, P4HB and SERPINA1 could be the promising diagnostic biomarkers and therapeutic targets of bladder cancer.Keywords: peptide, therapeutic target, progression, bladder cancer

Keywords